miRNA Biomarker Panel for Early PDAC Detection Beyond CA19-9
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current blood-based biomarkers, such as CA19-9, lack sensitivity and specificity for the early detection of pancreatic ductal adenocarcinoma (PDAC), with only 15-25% of patients exhibiting elevated levels, and 5-10% of the population being Lewis antigen-negative, limiting effective screening and treatment opportunities.
Innovation Solution
Utilizing a panel of cell-free and exosomal microRNAs, including miR-30c-5p, miR-142-3p, miR-340-5p, and exosomal miR-145-5p, for diagnosing PDAC by detecting elevated expression levels, combined with anti-cancer agents, radiation therapy, or surgical intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CA19-9 is used as a serum biomarker for PDAC detection, then it is widely available and commonly used, but it lacks sensitivity and specificity with only 15-25% of patients exhibiting elevated levels
Solution Approach 1:
The patent combines multiple miRNA biomarkers (miR-30c-5p, miR-142-3p, miR-340-5p, miR-335-5p, miR-23b-3p) into a panel to detect PDAC. This merging of multiple detection targets overcomes the limitation of single biomarker (CA19-9) low sensitivity by increasing the proportion of detectable patients through alternative biomarker expression patterns.
Solution Approach 2:
The patent shifts from detecting protein-based biomarkers (CA19-9) to detecting RNA-based biomarkers (miRNAs) with different biological properties and expression patterns. This parameter change in biomarker type enables detection of patients who would not show elevated CA19-9 levels, thereby improving detection coverage.
2Ease of operation
If a single biomarker like CA19-9 is used, then the testing is simple and cost-effective, but it fails to detect 75-85% of early-stage PDAC patients
Solution Approach 1:
The patent merges multiple miRNA markers into a single panel assay that can be processed together, maintaining operational simplicity while dramatically improving early detection accuracy from 15-25% to significantly higher levels by capturing diverse biomarker expression patterns.
Solution Approach 2:
The miRNA panel serves multiple functions: it detects early-stage PDAC, identifies patients with normal CA19-9 levels, and provides a universal screening tool applicable to all patients regardless of their CA19-9 status, thereby improving measurement precision without sacrificing ease of operation.
3Reliability
If CA19-9 levels are used for screening, then the method is established and standardized, but it misses 5-10% of Lewis antigen-negative population and early-stage patients
Solution Approach 1:
The patent changes the biomarker parameter from protein-based CA19-9 to RNA-based miRNAs, which are not affected by Lewis antigen status. This enables the screening method to adapt to and cover the 5-10% Lewis antigen-negative population and early-stage patients who were previously missed.
Solution Approach 2:
The miRNA panel provides universal applicability across all patient populations including Lewis antigen-negative individuals and early-stage patients, while maintaining standardized testing procedures through qRT-PCR methodology.
Data Source
AI summary
Provided herein, inter alia, are methods of diagnosing, monitoring, detecting, or treating pancreatic cancer in a patient by detecting the expression levels of RNA biomarkers in a biological sample.